Stimulation of angiotensin AT2receptors by the non‐peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and purpose: Angiotensin type 2 receptor (AT 2 receptor) stimulation evokes vasodilator effects in vitro and in vivo that oppose the vasoconstrictor effects of angiotensin type 1 receptors (AT 1 receptors). Recently, a novel non‐peptide AT 2 receptor agonist, Compound 21, was described, which exhibited high AT 2 receptor selectivity. Experimental approach: Functional cardiovascular effects of the drug candidate Compound 21 were assessed, using mouse isolated aorta and rat mesenteric arteries in vitro and in conscious spontaneously hypertensive rats (SHR). Key results: Compound 21 evoked dose‐dependent vasorelaxations in aortic and mesenteric vessels, abolished by the AT 2 receptor antagonist, PD123319.In vivo, Compound 21 administered alone, at doses ranging from 50 to 1000 ng·kg−1·min−1 over 4 h did not decrease blood pressure in conscious normotensive Wistar‐Kyoto rats or SHR. However, when given in combination with the AT 1 receptor antagonist, candesartan, Compound 21 (300 ng·kg−1·min−1) lowered blood pressure in SHR only. Further analysis in separate groups of conscious SHR revealed that, at a sixfold lower dose, Compound 21 (50 ng·kg−1·min−1) still evoked a significant depressor response in adult SHR (∼30 mmHg) when combined with different doses of candesartan (0.01 or 0.1 mg·kg−1). Moreover, the Compound 21‐evoked depressor effect was abolished when co‐infused (50 µg·kg−1·min−1 for 2 h) with the AT 2 receptor antagonist PD123319. Conclusion and implications: Collectively, our results indicate that acute administration of Compound 21 evoked blood pressure reductions via AT 2 receptor stimulation. Thus Compound 21 can be considered an excellent drug candidate for further study of AT 2 receptor function in cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Cited by
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors
Bosnyak, S., Jones, E. S., Christopoulos, A., Aguilar, M.-I., Thomas, W. G., & Widdop, R. E. (2011) · Clinical Science · doi:10.1042/cs20110036 · Cited by 288
Self-citationAngiotensin II and the vascular phenotype in hypertension
Savoia, C., Burger, D., Nishigaki, N., Montezano, A., & Touyz, R. M. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001815 · Cited by 198
“325, 449-454 153 Bosnyak, S. et al. (2010) Stimulation of angiotensin”
NADPH Oxidases and Mitochondria in Vascular Senescence
Salazar, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051327 · Cited by 133
Metadata
- Authors
- Bosnyak, S., Welungoda, I., Hallberg, A., Alterman, M., Widdop, R., & Jones, E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-02
- Volume
- 159
- Issue
- 3
- Pages
- 709-716
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1517126484
- Cited by
- 139
- References
- 1
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.